Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women

This study has been terminated.
(Failure to recruit.)
Information provided by (Responsible Party):
Duke University Identifier:
First received: February 20, 2013
Last updated: May 17, 2013
Last verified: March 2013
Results First Received: February 25, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Depression
Interventions: Drug: Placebo
Drug: Escitalopram

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Sugar Pill Placebo
Active Drug Escitalopram tablet, 10mg, daily, 9 weeks.

Participant Flow:   Overall Study
    Sugar Pill   Active Drug
STARTED   3 [1]   2 
COMPLETED   0 [1]   0 
[1] Terminated due to lack of enrollment

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Terminated study. Study terminated prior to interventions

Reporting Groups
Sugar Pill Placebo
Active Drug Escitalopram tablet, 10mg, daily, 9 weeks.
Total Total of all reporting groups

Baseline Measures
   Sugar Pill   Active Drug   Total 
Overall Participants Analyzed 
[Units: Participants]
 3   2   5 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   3   2   5 
>=65 years   0   0   0 
[Units: Participants]
Female   3   2   5 
Male   0   0   0 
Region of Enrollment 
[Units: Participants]
United States   3   2   5 

  Outcome Measures

1.  Primary:   Reduction in Depressive Symptoms   [ Time Frame: 9 weeks. ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.